newsfilter
← Latest News
GlobeNewswire·

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include